文献速递乳腺乳腺X线

乳腺癌检出方法与肿瘤特征、治疗及总生存期的关联:倾向性评分匹配分析

Associations of Breast Cancer Method of Detection With Tumor Characteristics, Treatments, and Overall Survival: A Propensity-Score-Matched Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2025-06-18

该回顾性研究纳入2010年1月1日至2020年1月1日活检证实的乳腺癌患者,按筛查检出(无症状筛查钼靶)或临床检出(有症状就诊)分组,并进行倾向性评分匹配。匹配后每组507例,筛查检出组肿瘤更小、分期更早、治疗强度更低,5年及10年总生存率均显著更高。

要点

  • 筛查检出组肿瘤1-10mm比例为42.0%,临床检出组为13.0%(p < .001)。
  • 筛查检出组5年生存率94.4%,临床检出组79.6%(p < .001)。
  • 筛查检出组10年生存率82.7%,临床检出组66.1%(p < .001)。

核心结论

  • 筛查检出的乳腺癌相比临床检出者与更小肿瘤尺寸、更早分期、创伤更小的治疗及更优总生存期相关。

研究设计与样本

  • 回顾性研究,纳入2010年1月1日至2020年1月1日活检证实的乳腺癌患者;匹配前筛查检出组932例、临床检出组528例,倾向性评分匹配后每组各507例;匹配因素包括年龄、种族、民族、保险状态和诊断年份;筛查检出组在Kaplan-Meier分析中纳入0.5年领先时间偏倚校正。

诊断标准与关键数值

  • 倾向性评分匹配后,筛查检出组平均年龄61.2岁,临床检出组平均年龄62.0岁。
  • 肿瘤大小1-10mm在筛查检出组占42.0%,临床检出组占13.0%(p < .001)。
  • 非浸润性疾病、局限性疾病、区域性疾病和远处转移性疾病频率:筛查检出组分别为35.5%、54.0%、9.9%、0.0%,临床检出组分别为8.9%、47.3%、34.1%、7.7%(p < .001)。
  • 手术治疗频率:肿块切除筛查检出组66.1% vs 临床检出组39.3%,乳房切除筛查检出组22.1% vs 临床检出组34.3%(p < .001)。
  • 放疗频率筛查检出组50.1% vs 临床检出组41.2%(p = .006);化疗频率筛查检出组15.0% vs 临床检出组40.2%(p < .001)。

临床应用与阅片要点

  • 筛查检出组5年生存率94.4% vs 临床检出组79.6%(p < .001),10年生存率82.7% vs 66.1%(p < .001)。
  • Kaplan-Meier曲线显示筛查检出组总生存期显著更优(p < .001),且随诊断后时间延长生存差异逐渐增大。
  • 作者认为研究结果为钼靶筛查提供了强有力的证据支持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. A contributor to variable breast cancer screening guidelines has been limited research assessing associations of the method of cancer detection with cancer outcomes. OBJECTIVE. The purpose of this study is to compare tumor characteristics, treatments, and survival outcomes between patients with breast cancer detected by mammographic screening versus by clinical symptoms. METHODS. This retrospective study included patients with biopsy-proven breast cancer from January 1, 2010, to January 1, 2020. For each patient, the method of detection was classified as screening-detected (i.e., screening mammography in the absence of symptoms) or clinically detected (i.e., presentation with symptoms leading to diagnostic imaging). Propensity-score matching was performed between the screening-detected and clinically detected cohorts by age, race, ethnicity, insurance status, and year of diagnosis. Tumor characteristics, treatments, and overall survival rates were compared between cohorts. Overall survival was compared between cohorts using Kaplan-Meier curves, incorporating a 0.5-year lead time bias adjustment in the screening-detected cohort. RESULTS. Before propensity-score matching, the analysis included 1460 patients with breast cancer (screening-detected cohort, 932 patients; clinically detected cohort, 528 patients). After propensity-score matching, each cohort included 507 patients (mean age in the screening-detected and clinically diagnosed cohorts of 61.2 and 62.0 years, respectively). Tumor size measured 1-10 mm in 42.0% of screening-detected cancers versus in 13.0% of clinically detected cancers (p < .001). Frequencies of noninvasive disease, localized disease, regional disease, and distant metastatic disease were 35.5%, 54.0%, 9.9%, and 0.0% in the screening-detected cohort versus 8.9%, 47.3%, 34.1%, and 7.7% in the clinically detected cohort, respectively (p < .001). Screening-detected and clinically detected cohorts showed significant differences in frequencies of surgical therapies (lumpectomy, 66.1% vs 39.3%; mastectomy, 22.1% vs 34.3%; p < .001), radiation therapy (50.1% vs 41.2%; p = .006), and chemotherapy (15.0% vs 40.2%; p < .001). The screening-detected in comparison with the clinically detected cohort showed significantly greater 5-year survival rate (94.4% vs 79.6%; p < .001) and 10-year survival rate (82.7% vs 66.1%; p < .001). Kaplan-Meier curves indicated significantly greater overall survival in the screening-detected cohort (p < .001), with a progressively increasing difference in survival with increasing time since diagnosis. CONCLUSION. Screening-detected cancers in comparison with clinically detected cancers were associated with smaller size, earlier stage, less-invasive therapies, and improved overall survival. CLINICAL IMPACT. The findings provide strong evidence supporting mammographic screening.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Chen SJ, Rahman A, Choi AY, et al. Associations of Breast Cancer Method of Detection With Tumor Characteristics, Treatments, and Overall Survival: A Propensity-Score-Matched Analysis. AJR Am J Roentgenol. 2025. PMID: 40532169. doi:10.2214/AJR.25.33245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。